Webcasts Event RSS
Upcoming Events Past Events
Cantor Fitzgerald Global Healthcare Conference
October 1, 2018
View the live Webcast
2018 Wells Fargo Securities Healthcare Conference
September 6, 2018
View the live Webcast
Canaccord Genuity 38th Annual Growth Conference
August 9, 2018
View the live Webcast

Investor Materials

Thumb Date Download
July 20, 2018 Corporate Presentation 1.10 MB
December 31, 2017 2017 Annual Report 3.18 MB
July 24, 2016 2016 Annual Report 4.75 MB
July 23, 2016 2015 Annual Report 5.24 MB
July 21, 2016 2014 Annual Report 2.13 MB

Recent News

Date Title Press Release RSS
Halozyme Therapeutics To Participate In Upcoming Investor Conference 09/20/18
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada 09/17/18
Halozyme Appoints Bernadette Connaughton To Board Of Directors 09/10/18
Halozyme Names Benjamin Hickey As Chief Commercial Officer 09/05/18
See More

Stock Quote

HALO (NASDAQ) $17.26 +0.21 +1.23% Volume: 589,349 Pricing delayed 20 minutes September 20, 2018

Investor Contacts

Robert H. Uhl
Managing Director
Westwicke Partners, LLC
Phone: 858-356-5932
Email: robert.uhl@westwicke.com
media@halozyme.com
ir@halozyme.com

Useful Links

Contact Info


Office:

Halozyme
11388 Sorrento Valley Road
San Diego, CA 92121
Phone: 858.794.8889
info@halozyme.com

Recent News

September 20, 2018 Halozyme Therapeutics To Participate In Upcoming Investor Conference
September 17, 2018 Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada
September 10, 2018 Halozyme Appoints Bernadette Connaughton To Board Of Directors
Copyright © 2015-2017 . Halozyme, Inc. All rights reserved. All trademarks belong to their respective owners.
Powered By Q4 Inc. 5.12.0.7

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok